Suchergebnisse - "Shi, Yuankai"

PubPharm (531)

41

$ MYD88^{L265P} $ and $ MYD88^{other} $ variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma

enthalten in: Journal of cancer research and clinical oncology | 2023

von Qin, Y. | Qiu, T. | Xie, Z. | +11

42

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer : a phase Ib study

enthalten in: BMC cancer | 2023

von Hu, X. | Cui, X. | Wang, Z. | +16

43

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

enthalten in: BMC cancer | 2023

von Hu, X. | Cui, X. | Wang, Z. | +16

44

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

enthalten in: BMC cancer | 2023

von Hu, X. | Cui, X. | Wang, Z. | +16

45

Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer

enthalten in: BMC cancer | 2023

von Huang, L. | Feng, Y. | Xie, T. | +3

46

Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC

enthalten in: Cancer immunology immunotherapy | 2023

von Wang, S. | Fan, G. | Li, L. | +8

47

Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC

enthalten in: Cancer immunology immunotherapy | 2023

von Wang, S. | Fan, G. | Li, L. | +8

48

Polypeptide marker based on autoantibody and application of polypeptide marker in early lung cancer diagnosis

enthalten in: Europäisches Patentamt | 2023

von HAN XIAOHONG | SHI YUANKAI | LI YINGRUI | +2

49

Validation of the IMPROVE bleeding risk assessment model in surgical patients : Results from the DissolVE-2 Study

enthalten in: Thrombosis research | 2023

von Zhang, Z. | Zhen, K. | Li, W. | +11

50

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients : a single-arm, multicenter phase II study (INTELLECT)

enthalten in: BMC medicine | 2023

von Shi, Y. | Chen, J. | Zhang, H. | +30